Metformin Dosing and Monitoring in Patients with Reduced Kidney Function

Dosing Strategy

The American Diabetes Association and the National Kidney Foundation recommend continuing metformin at standard dosing without mandatory dose reduction at an eGFR of 45 mL/min/1.73m², but consider reducing the dose in patients with advanced age or concomitant liver disease 1, 2
The maximum daily dose can remain up to 2000-2550 mg divided throughout the day in patients with eGFR 45-59 mL/min/1.73m² 1
Dose reduction to half the maximum dose (1000-1250 mg daily) should be considered in patients with advanced age, concomitant liver disease, or other risk factors for lactic acidosis 1, 2, 3

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend monitoring eGFR every 3-6 months when eGFR is <60 mL/min/1.73m² 1, 4, 2
Vitamin B12 levels should be checked if metformin use exceeds 4 years 1, 2, 5

At eGFR 30-44 mL/min/1.73m², the dose should be reduced to half the maximum (typically 1000 mg daily maximum) 1, 2, 3
Metformin should be discontinued completely at eGFR <30 mL/min/1.73m², as this is an absolute contraindication 1, 2, 3

Metformin remains first-line therapy for type 2 diabetes with CKD and eGFR ≥30, with strong evidence (Grade 1B recommendation) 1, 5
The potential cardiovascular and mortality benefits of metformin may outweigh the minimal lactic acidosis risk when used appropriately 1, 5